Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Ragosa Mark

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/17/2020

3. Issuer Name and Ticker or Trading Symbol

Kiniksa Pharmaceuticals, Ltd. [KNSA]

(Last) (First) (Middle)

CLARENDON HOUSE, 2 CHURCH STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Interim CFO /

(Street)

HAMILTON, D0 HM 11

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option	⁽¹⁾	5/22/2028	Class A Common Shares	18299	$18.00	D
Share Option	⁽²⁾	9/19/2028	Class A Common Shares	20000	$30.93	D
Share Option	⁽³⁾	3/3/2029	Class A Common Shares	12000	$17.92	D
Share Option	⁽⁴⁾	9/16/2029	Class A Common Shares	12000	$8.83	D
Share Option	⁽⁵⁾	3/12/2030	Class A Common Shares	20000	$15.52	D
Share Option	⁽⁶⁾	9/9/2030	Class A Common Shares	22000	$15.50	D
Restricted Share Units	⁽⁷⁾	⁽⁷⁾	Class A Common Shares	4404	⁽⁸⁾	D

Explanation of Responses:
(1)	The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is May 10, 2018.
(2)	The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 20, 2018.
(3)	The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.
(4)	The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.
(5)	The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.
(6)	The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.
(7)	The Restricted Share Units (RSU) will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU.
(8)	Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.

Remarks:
Exhibit 24 - Power of Attorney.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Ragosa Mark CLARENDON HOUSE 2 CHURCH STREET HAMILTON, D0 HM 11			Interim CFO